← back to search

Niranjan Y. Sardesai

Genex Systems (United States) ·
Area of research
Immunology · Biotechnology
Research interest
Research interests include Immunotherapy and Immune Responses, HIV Research and Treatment, Transgenic Plants and Applications, and Immune Cell Function and Interaction.
h-index
47
citations
7,288
works
207
NIH funding
primary concept
Biology
email

Recent publications

Personalized neoantigen vaccine and pembrolizumab in advanced hepatocellular carcinoma: a phase 1/2 trial
Nature Medicine 2024cited by 209position: lastdoi
Robust antibody and cellular responses induced by DNA-only vaccination for HIV
JCI Insight 2020cited by 47position: middledoi
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
Vaccines 2020cited by 27position: middledoi
In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model
Cell Reports 2018cited by 50position: middledoi
Intradermal Delivery of INO-4201 Drives Robust Ebola Glycoprotein Specific Humoral and Cellular Immune Responses in Healthy Volunteers in an Open Label Phase I Trial
The Journal of Immunology 2017cited by 1position: middledoi
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
The Lancet 2015cited by 706position: middledoi
Chemokine-adjuvanted electroporated DNA vaccine induces substantial protection from simian immunodeficiency virus vaginal challenge
Mucosal Immunology 2015cited by 33position: middledoi
Activated CD4 <sup>+</sup> CCR5 <sup>+</sup> T cells in the rectum predict increased SIV acquisition in SIVGag/Tat-vaccinated rhesus macaques
Proceedings of the National Academy of Sciences 2014cited by 83position: middledoi
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
The Journal of Infectious Diseases 2013cited by 196position: middledoi
DNA and virus particle vaccination protects against acquisition and confers control of viremia upon heterologous simian immunodeficiency virus challenge
Proceedings of the National Academy of Sciences 2013cited by 76position: middledoi
Therapeutic DNA Vaccination Using In Vivo Electroporation Followed by Standard of Care Therapy in Patients With Genotype 1 Chronic Hepatitis C
Molecular Therapy 2013cited by 76position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

Jian Yan · Dalian Institute of Chemical Physics6 papers (2014–2024)David B. Weiner · The Wistar Institute6 papers (2014–2024)Amir Sada Khan · Shenzhen University4 papers (2015–2020)Matthew P. Morrow · University of Florida4 papers (2014–2020)Jean Boyer · Celsion (United States)3 papers (2015–2020) · 3 papers (2015–2020)Albert J. Sylvester · Drexel University3 papers (2015–2017) · 2 papers (2013–2015) · 2 papers (2015–2017) · 2 papers (2015–2020)S. M. White · University of South Carolina2 papers (2017–2020) · 2 papers (2015–2017)Ami Patel · University of Florida1 papers (2017–2017)Lars Frelin · Karolinska University Hospital1 papers (2013–2013)Elizabeth M. Jaffee · NYU Langone Health1 papers (2024–2024)Yongjun Guan · Guangzhou Medical University1 papers (2013–2013)Yiwen Lu · Florida College1 papers (2020–2020)Xiaoying Shen · Ministry of Education of the People's Republic of China1 papers (2013–2013) · 1 papers (2014–2014) · 1 papers (2013–2013)